```
================================================================
Sequence Listing was accepted.
See attached Validation Report.
If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).
Reviewer: Durreshwar Anjum
Timestamp: [year=2010; month=10; day=20; hr=12; min=58; sec=45; ms=481;
]
================================================================
```

Application No: 10591486   Version No: 2.0

                    Input Set:

                    Output Set:

                    Started: 2010-10-15 11:26:09.048
                   Finished: 2010-10-15 11:26:12.756
                    Elapsed: 0 hr(s) 0 min(s) 3 sec(s) 708 ms
            Total Warnings: 4
              Total Errors: 12
      No. of SeqIDs Defined: 8
        Actual SeqID Count: 8

Error code   Error Description

W   213   Artificial or Unknown found in <213> in SEQ ID (1)

E   257   Invalid sequence data feature in <221> in SEQ ID (1)

E   257   Invalid sequence data feature in <221> in SEQ ID (1)

E   257   Invalid sequence data feature in <221> in SEQ ID (1)

E   257   Invalid sequence data feature in <221> in SEQ ID (2)

E   257   Invalid sequence data feature in <221> in SEQ ID (2)

E   257   Invalid sequence data feature in <221> in SEQ ID (3)

E   257   Invalid sequence data feature in <221> in SEQ ID (3)

E   257   Invalid sequence data feature in <221> in SEQ ID (4)

E   257   Invalid sequence data feature in <221> in SEQ ID (4)

W   213   Artificial or Unknown found in <213> in SEQ ID (5)

W   213   Artificial or Unknown found in <213> in SEQ ID (6)

E   257   Invalid sequence data feature in <221> in SEQ ID (6)

E   257   Invalid sequence data feature in <221> in SEQ ID (6)

E   257   Invalid sequence data feature in <221> in SEQ ID (6)

W   213   Artificial or Unknown found in <213> in SEQ ID (8)

<110>   Waugh, Jacob
         Dake, Michael

<120>   Compositions and Methods for Topical Diagnostic and Therapeutic
         Transport

<130>   13720-105068US2

<140>   10591486
<141>   2010-10-15

<150>   US 11/073,307
<151>   2005-03-03

<150>   US 60/550,014
<151>   2004-03-03

<160>   8

<170>   PatentIn version 3.4

<210>   1
<211>   45
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic

<220>
<221>   MOD_RES
<222>   (1)..(20)
<223>   This region may encompass 0 to 20 Gly residues

<220>
<221>   MOD_RES
<222>   (1)..(45)
<223>   See specification as filed for detailed description of
         substitutions and preferred embodiments

<220>
<221>   MOD_RES
<222>   (21)..(45)
<223>   This region may encompass an odd number of Arg residues from 5 to
         25

<400>   1

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
1   5   10   15

Gly Gly Gly Gly Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
            35   40   45

<210>   2
<211>   51
<212>   PRT
<213>   Human immunodeficiency virus

<220>
<221>   misc_feature
<222>   (1)..(51)
<223>   See specification as filed for detailed description of
        substitutions and preferred embodiments

<220>
<221>   MOD_RES
<222>   (32)..(51)
<223>   This region may encompass 0 to 20 residues

<220>
<221>   MOD_RES
<222>   (32)..(51)
<223>   This region may encompass 0 to 20 residues

<400>   2

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
1   5   10   15

Gly Gly Gly Gly Arg Gly Arg Asp Asp Arg Arg Gln Arg Arg Arg Gly
            20   25   30

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
            35   40   45

Gly Gly Gly
    50

<210>   3
<211>   51
<212>   PRT
<213>   Human immunodeficiency virus

<220>
<221>   MOD_RES
<222>   (1)..(20)
<223>   This region may encompass 0 to 20 Gly residues

<220>
<221> misc_feature
<222> (1)..(51)
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<220>
<221> MOD_RES
<222> (32)..(51)
<223> This region may encompass 0 to 20 Gly residues

<400> 3

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
1   5   10   15

Gly Gly Gly Gly Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly
            20   25   30

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
        35   40   45

Gly Gly Gly
    50

<210> 4
<211> 49
<212> PRT
<213> Human immunodeficiency virus

<220>
<221> MOD_RES
<222> (1)..(20)
<223> This region may encompass 0 to 20 Gly residues

<220>
<221> misc_feature
<222> (1)..(49)
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<220>
<221> MOD_RES
<222> (30)..(49)
<223> This region may encompass 0 to 20 Gly residues

<400> 4

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
1   5   10   15

Gly Gly Gly Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Gly
            20   25   30

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly
        35   40   45

Gly

<210>   5
<211>   10
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic

<400>   5

Gly Gly Gly Arg Arg Arg Arg Arg Arg Arg
1   5   10

<210>   6
<211>   22
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic

<220>
<221>   MOD_RES
<222>   (1)..(5)
<223>   This region may encompass 3 to 5 Gly residues

<220>
<221>   MOD_RES
<222>   (1)..(22)
<223>   See specification as filed for detailed description of
        substitutions and preferred embodiments

<220>
<221>   MOD_RES
<222>   (5)..(22)
<223>   This region may encompass an odd number of Arg residues from 7
        through 17

<400>   6

Gly Gly Gly Gly Gly Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
1   5   10   15

Arg Arg Arg Arg Arg Arg
            20

<210>   7
<211>   12
<212>   PRT
<213>   Human immunodeficiency virus

<400>   7

Gly Gly Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg
1   5   10

<210>   8
<211>   9
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthetic

<400>   8

Arg Arg Arg Arg Arg Arg Arg Arg Arg
1   5